| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 143MM | +4% |
| Operating Income | -113.5MM | -5% |
| Operating Expenses | 256.6MM | - |
| Net Income | -86.1MM | +18% |
| R&D | 93.9MM | +4% |
| G&A | 36.2MM | -13% |
| Marketing | 68.9MM | -3% |
| Amortization | 700K | - |
| Interest Expense | 644K | -0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Guardant Health Inc (NASDAQ:GH), a leading precision oncology company, has recently witnessed a significant insider sell by its Chief Information Officer, Kumud Kalia.
LONDON & PALO ALTO, Calif., December 04, 2023--Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment.
PALO ALTO, Calif., November 30, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas. Highlights of the eight poster presentations include the use of blood-based testing to identify actionable biomarkers and predict therapy response in advanced breast cancer, and to detect residual diseas
PALO ALTO, Calif., November 15, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on November 8, 2023, the Compensation Committee of Guardant’s Board of Directors granted restricted stock units ("RSUs") representing 50,741 shares of its common stock to 43 new non-executive employees under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs were granted as inducements material to the employe
PALO ALTO, Calif., November 15, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
Guardant Health, Inc. (NASDAQ:GH) Q3 2023 Earnings Call Transcript November 6, 2023 Guardant Health, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.93. Operator: Hello, everyone, and welcome to the Guardant Health Q3 2023 Earnings Call. My name is Thrisha, and I’ll be your operator today. [Operator Instructions] I will now hand you […]
Q3 2023 Guardant Health Inc Earnings Call
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Company's clinical volume growth drives revenue increase and raises 2023 revenue guidance